Oncology Xagena
An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ( NSCLC ) met its primary efficacy endpoint ...
ProMune is a synthetic agonist for Toll-like receptor 9 ( TLR9 ). By stimulating TLR9, ProMune acts directly and selectively on plasmacytoid dendritic cells and B cells to reverse immune tolerance to ...
Erlotinib ( Tarceva ) is the first drug and the only EGFR-targeted treatment shown to prolong survival in a phase III trial ( PA3 ) when added to standard of care ( Gemcitabine ) for the treatment of ...
A randomized study of Erlotinib ( Tarceva ) plus Gemcitabine met its primary endpoint by demonstrating a statistically significant 23.5 percent improvement in overall survival ( or a hazard ratio of 0 ...
Data from a study ( E4599 ) of Bevacizumab ( Avastin ) plus Paclitaxel and Carboplatin in first-line non-squamous, non-small cell lung cancer ( NSCLC ) showed the study met its primary efficacy endpoi ...
An experimental compound, ABT-737, that blocks the action of a class of proteins known as the Bcl-2 family, may prove to be a valuable tool in the fight against cancer. The Bcl-2 family of protein ...
Tarceva ( Erlotinib ) has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of non-small cell lung cancer, the most common ...
A study, led by Canadian researchers, has demonstrated that Erlotinib ( Tarceva ) increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options. ...
According to Researchers from Dana-Farber Cancer Institute in Boston, Tarceva ( Erlotinib ), a tyrosine kinase inhibitor, showed encouraging activity with relatively tolerable side effects in elderly, ...
Researchers at Washington University School of Medicine in St. Louis reported that a compound related to vitamin A shows promise in preventing or slowing tumor growth in mice prone to lung cancer. Th ...
A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. This ...
Researchers at the Ireland Cancer Center of University Hospitals of Cleveland have found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and ...
Researchers evaluate the effectiveness of a new antitumoral therapy by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer ( NSCLC ), there may be a better way ...
The drug Motexafin Gadolinium ( Xcytrin ), based on a molecule developed by chemists at The University of Texas at Austin, showed significant promise in prolonging cognitive function in patients with ...
Researchers at The University of Texas M. D. Anderson Cancer Center have evaluated a new type of drug that activates "death" receptors on cancer cells, and have found it to be both safe and suggestiv ...
